227 related articles for article (PubMed ID: 23645448)
1. Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
Vlachostergios PJ; Hatzidaki E; Befani CD; Liakos P; Papandreou CN
Invest New Drugs; 2013 Oct; 31(5):1169-81. PubMed ID: 23645448
[TBL] [Abstract][Full Text] [Related]
2. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
Persano L; Pistollato F; Rampazzo E; Della Puppa A; Abbadi S; Frasson C; Volpin F; Indraccolo S; Scienza R; Basso G
Cell Death Dis; 2012 Oct; 3(10):e412. PubMed ID: 23076220
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
4. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS
Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901
[TBL] [Abstract][Full Text] [Related]
5. MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.
Vlachostergios PJ; Hatzidaki E; Papandreou CN
Neurol Res; 2013 Oct; 35(8):879-82. PubMed ID: 23561593
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Rahman MA; Gras Navarro A; Brekke J; Engelsen A; Bindesbøll C; Sarowar S; Bahador M; Bifulco E; Goplen D; Waha A; Lie SA; Gjertsen BT; Selheim F; Enger PØ; Simonsen A; Chekenya M
Br J Cancer; 2019 Oct; 121(7):545-555. PubMed ID: 31413318
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib downregulates MGMT expression in T98G glioblastoma cells.
Vlachostergios PJ; Hatzidaki E; Stathakis NE; Koukoulis GK; Papandreou CN
Cell Mol Neurobiol; 2013 Apr; 33(3):313-8. PubMed ID: 23334228
[TBL] [Abstract][Full Text] [Related]
8. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
[TBL] [Abstract][Full Text] [Related]
9. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Ramcharan R; Aleksic T; Kamdoum WP; Gao S; Pfister SX; Tanner J; Bridges E; Asher R; Watson AJ; Margison GP; Woodcock M; Repapi E; Li JL; Middleton MR; Macaulay VM
Oncotarget; 2015 Nov; 6(37):39877-90. PubMed ID: 26497996
[TBL] [Abstract][Full Text] [Related]
10. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
11. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
12. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Huang H; Lin H; Zhang X; Li J
Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.
Chalmers AJ; Ruff EM; Martindale C; Lovegrove N; Short SC
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1511-9. PubMed ID: 19931733
[TBL] [Abstract][Full Text] [Related]
15. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
16. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)
Kochanowski P; Catapano J; Pudełek M; Wróbel T; Madeja Z; Ryszawy D; Czyż J
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923767
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
Wu M; Song D; Li H; Ahmad N; Xu H; Yang X; Wang Q; Cheng X; Deng S; Shu X
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298405
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.
Befani CD; Vlachostergios PJ; Hatzidaki E; Patrikidou A; Bonanou S; Simos G; Papandreou CN; Liakos P
J Mol Med (Berl); 2012 Jan; 90(1):45-54. PubMed ID: 21909688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
